Literature DB >> 15114629

Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein.

Kang-Woo Lee1, Si Hyoung Lee, Hyuck Kim, Jin-Sook Song, Sung-Don Yang, Sang Gi Paik, Pyung-Lim Han.   

Abstract

Numerous transgenic mouse models for Alzheimer's disease (AD) have been generated to recapitulate the histological pathogenesis and behavioral phenotypes of AD brain. However, none of the existing models exhibits the full spectrum of AD symptoms, nor have all of the traits mimicked by the developed animal models been successfully represented within a single mouse line, indicating that the development of transgenic lines showing new features of the AD-like brain should be explored. Here we report on a transgenic mouse line, named Tg-APP (Sw, V717F)/B6, that expresses the human amyloid precursor protein (APP) containing the Swedish and the V717F Indiana mutations in the brains of inbred C57BL/6 mice, designed to eliminate the potential phenotypic variations attributed to the compound genetic backgrounds adopted in most AD mouse models. The Tg-APP (Sw, V717F)/B6 mice expressed the transgene transcript, in the heterozygote state, at a level of 2.6 +/- 0.1 fold higher than that of endogenous mouse APP. However, no Abeta-plaque deposition was produced in the brain of the Tg-APP (Sw, V717F)/B6 mice up to 18 months of age. The Tg-APP(Sw, V717F)/B6 mice at 13-15 months showed reduced expression of calbindin and c-Fos in the brain. The Tg-APP (Sw, V717F)/B6 mice at 11-14 months displayed decreased motor coordination, learning and memory deficits, and severely increased anxiety. These phenotypes were not observed in the Tg-APP (Sw, V717F)/B6 mice at 5-7 months. Microarray analysis revealed altered expression, in the amygdala of the Tg-APP (Sw, V717F)/B6 mice, of genes previously implicated in anxiety. Taken together, these results suggest that the transgenic APP, or its derivatives, produces the age-dependent pathophysiology of the AD-like brain and that the progressive cognitive impairment and anxiety induction can proceed in the absence of visible Abeta-plaque deposition. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15114629     DOI: 10.1002/jnr.20127

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  30 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

2.  Subfield and layer-specific depletion in calbindin-D28K, calretinin and parvalbumin immunoreactivity in the dentate gyrus of amyloid precursor protein/presenilin 1 transgenic mice.

Authors:  M Popović; M Caballero-Bleda; I Kadish; T Van Groen
Journal:  Neuroscience       Date:  2008-05-24       Impact factor: 3.590

3.  Oligonucleotide-based analysis of differentially expressed genes in hippocampus of transgenic mice expressing NSE-controlled APPsw.

Authors:  Seung W Jee; Jung S Cho; Chuel K Kim; Dae Y Hwang; Sun B Shim; Su H Lee; Ji S Sin; Jin H Park; Yang S Kim; Soo Y Choi; Yong K Kim
Journal:  Neurochem Res       Date:  2006-08-08       Impact factor: 3.996

4.  The effects of MyD88 deficiency on exploratory activity, anxiety, motor coordination, and spatial learning in C57BL/6 and APPswe/PS1dE9 mice.

Authors:  Jeong-Eun Lim; Min Song; Jingji Jin; Jinghong Kou; Abhinandan Pattanayak; Robert Lalonde; Ken-Ichiro Fukuchi
Journal:  Behav Brain Res       Date:  2011-10-21       Impact factor: 3.332

5.  Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer's disease.

Authors:  Hisaaki Takahashi; Ivona Brasnjevic; Bart P F Rutten; Nicolien Van Der Kolk; Daniel P Perl; Constantin Bouras; Harry W M Steinbusch; Christoph Schmitz; Patrick R Hof; Dara L Dickstein
Journal:  Brain Struct Funct       Date:  2010-03-07       Impact factor: 3.270

6.  Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease.

Authors:  M Cuadrado-Tejedor; I Hervias; A Ricobaraza; E Puerta; J M Pérez-Roldán; C García-Barroso; R Franco; N Aguirre; A García-Osta
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

7.  Rapamycin, Autophagy, and Alzheimer's Disease.

Authors:  Zhiyou Cai; Liang-Jun Yan
Journal:  J Biochem Pharmacol Res       Date:  2013-06

8.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Authors:  Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

9.  Progesterone reduces depression-like behavior in a murine model of Alzheimer's Disease.

Authors:  Cheryl A Frye; Alicia A Walf
Journal:  Age (Dordr)       Date:  2009-03-26

10.  Central CRF system perturbation in an Alzheimer's disease knockin mouse model.

Authors:  Qinxi Guo; Hui Zheng; Nicholas John Justice
Journal:  Neurobiol Aging       Date:  2012-02-14       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.